Company Overview


ZYUS is inspired by science. Born from the abstraction of ‘science’ and ‘zygote’ (the fusion of two cells), we represent the beginning of life and the importance of improving quality of life. We believe in taking a forward, collaborative approach and place high value in our teamwork, partnerships and commitment to the broader ‘us' - society. We believe that together, we can bring phyto-therapeutics to the global medical market.

ZYUS is a Canadian-based, next-generation life sciences company leading scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. We are committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.

We aim to shift the paradigm from conventional strategies to focus on improving our patients' overall quality of life and well-being by harnessing the power of cannabinoids. With science as our driver, we re-imagine the potential phyto-therapeutics as a standard of care for treating disease and managing the experience of it. To achieve this, we are investing in:

  • Upstream molecular biology
  • Traditional plant breeding
  • Molecule purification optimization
  • Pre-clinical model testing
  • Clinical trials
  • Advancing process manufacturing
  • Defining scientific standards
  • High-quality offerings
  • Raising awareness of medical needs

ZYUS was founded by Brent Zettl, the former President and CEO of CanniMed Therapeutics Inc. and other senior members of his management team. Brent and his team were the first and exclusive supplier of medical cannabis to Health Canada from 2000 to 2014. With decades of experience pioneering the medical cannabis industry, ZYUS has set a vision to elevate cannabinoids as a standard of care and reimagine the potential of medicine in pursuit of a transformational impact on patients’ lives.

ZYUS. Advancing the science of well-being.